Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dienogest

R H Foster1, M I Wilde

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 26, 1998
PubMed
Summary
This summary is machine-generated.

Dienogest, a progestogen, effectively prevents ovulation and contraception with minimal side effects. It also improves androgenic symptoms without negatively impacting metabolic or lipid parameters.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The authors' reply.

PharmacoEconomics·2016
Same author

Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

CNS drugs·2015
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Mycophenolate mofetil: a review of its use in the management of solid organ transplantation.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Tetravalent human-rhesus reassortant rotavirus vaccine: a review of its immunogenicity, tolerability and protective efficacy against paediatric rotavirus gastroenteritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Interferon-alpha-2a: a review of its use in chronic hepatitis C.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology
  • Gynecology

Background:

  • Progestogens are critical in hormonal therapies.
  • Dienogest is a selective progestogen with known antiandrogenic properties.
  • Understanding its full clinical profile is essential for therapeutic applications.

Purpose of the Study:

  • To evaluate the contraceptive efficacy and cycle stability of oral dienogest combined with ethinylestradiol.
  • To assess the impact of dienogest on androgenic symptoms.
  • To characterize the adverse event profile and metabolic effects of dienogest.

Main Methods:

  • Combination oral contraceptive therapy with dienogest (2 mg/day) and ethinylestradiol (30 µg/day).
  • Assessment of contraceptive efficacy using the Pearl Index.

Related Experiment Videos

  • Monitoring of cycle stability, bleeding patterns, androgenic symptoms, and adverse events.
  • Evaluation of metabolic, lipid, and hemostatic parameters.

    • Main Results:

    • Highly effective contraception with a Pearl Index of approximately 0.2.
    • Good cycle stability during long-term use, with irregular bleeding in 6% of women after 12 months.
    • Significant improvement in androgenic symptoms (hirsutism, acne, seborrhea).
    • Adverse events were typical for progestogens; no androgenic adverse effects observed.
    • Minimal clinically significant effects on metabolic, lipid, and hemostatic parameters.

    Conclusions:

    • Oral dienogest/ethinylestradiol provides reliable contraception and improves androgenic symptoms.
    • The combination demonstrates a favorable safety profile with minimal metabolic impact.
    • Dienogest is a valuable therapeutic option for conditions requiring contraception and management of androgenic symptoms.